Cornerstone Pharmaceutical was created to meet the needs of cancer patients and focuses on developing and commercializing innovative tumor immunotherapy and molecular-targeted drugs. Since its establishment 3 years ago, the company has assembled a world-class management team with rich experience in preclinical research, clinical development and commercialization. Through a dual source of innovation consisting of internal R&D and external collaboration, the company has built a powerful anti-tumor drug pipeline with 14 drug candidates, including 4 products exclusively collaborated and authorized by Blueprint Medicine and Agios Pharmaceuticals. Together with the self-developed pipeline, the company has significant potential and synergistic effects for single and combination therapies. Of the drug candidates under development, 4 are in or close to critical trials. Cornerstone Pharmaceutical's business model is driven by clinical research and development, while rapidly establishing commercialization and production capacity. The company received support from well-known investors, and both the A and B rounds of financing broke records in the biomedical field at the time, with a total amount of 412 million US dollars in the two rounds of financing. With an experienced team, a promising R&D pipeline, a strong business model, and sustainable financial support, Cornerstone's vision is to become a world-renowned leading Chinese biopharmaceutical company by bringing innovative and differentiated oncology therapies to cancer patients around the world.
相关临床试验
28
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
进行中（未招募）
2
7.1%
已完成
21
75.0%
尚未招募
1
3.6%
招募中
2
7.1%
暂停
1
3.6%
终止
1
3.6%
暂无批准数据
- CStone Pharmaceuticals signed an exclusive commercialization agreement with Arrotex Pharmaceuticals to bring sugemalimab to Australia and New Zealand. - Arrotex will handle regulatory submissions and commercialization across all approved and future indications, including NSCLC, gastric cancer, ESCC, and ENKTL. - CStone receives upfront and milestone payments plus profit share, marking sugemalimab's fifth international partnership covering over 60 countries. - Sugemalimab is already approved in the EU, UK, and China for multiple oncology indications, with ESMO Guidelines recommending its use in NSCLC.
- CStone Pharmaceuticals received FDA clearance for its Investigational New Drug application to advance CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, into Phase II clinical trials for advanced solid tumors. - The global multicenter Phase II trial features 15 cohorts evaluating monotherapy and combination regimens across 9 solid tumor indications, including non-small cell lung cancer, colorectal cancer, and triple-negative breast cancer. - Initial Phase I data presented at the 2025 ESMO meeting demonstrated a favorable safety profile with encouraging antitumor activities, with further clinical data expected at upcoming ASCO and ESMO conferences. - CS2009 combines three clinically validated targets to exert multidimensional anti-tumor effects through synergistic actions, with potential to be first- or best-in-class therapy.
- CStone Pharmaceuticals received a positive opinion from the European Medicines Agency's CHMP recommending approval of sugemalimab monotherapy for adults with unresectable stage III non-small cell lung cancer. - The recommendation is based on compelling Phase III data from the GEMSTONE-301 multicenter, randomized, double-blind clinical study demonstrating dual benefits in progression-free survival and overall survival. - If approved, sugemalimab would become the second PD-(L)1 antibody available in Europe for stage III NSCLC, addressing a critical unmet medical need in this disease area. - This marks the second positive CHMP opinion for sugemalimab within one year, following its first EMA approval in 2024 for first-line treatment of metastatic squamous and non-squamous NSCLC.
- CStone Pharmaceuticals disclosed the world's first clinical data for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, showing promising safety and efficacy in 72 patients with advanced solid tumors. - The Phase I study demonstrated favorable tolerability with no dose-limiting toxicities and achieved an overall response rate of 12.2% with a disease control rate of 71.4% despite limited follow-up. - CS2009 showed particularly encouraging results in specific tumor types, including 25% response rate in triple-negative breast cancer and 33.3% in non-clear cell renal cell carcinoma. - The company has initiated Phase II dose expansion studies in first-line patients with selected tumor types to support registration trials in NSCLC and other indications.
- The GEMSTONE-303 Phase III trial demonstrated that sugemalimab plus chemotherapy significantly improved overall survival to 15.6 months versus 12.6 months with chemotherapy alone in advanced gastric cancer patients with PD-L1 CPS ≥5. - Cost-effectiveness analysis revealed incremental cost-effectiveness ratios of $80,573.50 per QALY for CPS ≥5 patients and $64,428.81 per QALY for CPS ≥10 patients, both exceeding China's willingness-to-pay threshold of $40,344. - A 40% price reduction could make sugemalimab cost-effective in the CPS ≥10 subgroup, with a 48% probability of being economically viable at the current threshold. - Higher PD-L1 expression levels showed improved cost-effectiveness ratios, suggesting biomarker-driven patient selection could optimize treatment value.
- CStone Pharmaceuticals announced that China's National Medical Products Administration has approved the manufacturing localization application for GAVRETO (pralsetinib), enabling domestic production starting in 2026. - The approval allows end-to-end domestic production from active pharmaceutical ingredient to finished drug product, significantly enhancing supply chain flexibility and resilience for the Chinese market. - GAVRETO is a once-daily oral targeted therapy approved in China for treating RET fusion-positive non-small cell lung cancer and RET-mutant medullary thyroid carcinoma in adults and pediatric patients. - The localized manufacturing transition represents a key milestone in CStone's lifecycle management strategy and aims to improve treatment accessibility for RET-positive patients across China.
- CStone Pharmaceuticals has submitted a Phase Ib clinical trial application in Australia to evaluate CS5001 in combination with R-CHOP as first-line treatment for diffuse large B-cell lymphoma. - CS5001 has shown promising results in early trials, achieving 70% objective response rates in advanced B-cell lymphoma and 100% in Hodgkin lymphoma at the recommended Phase 2 dose. - The global multi-center trial will explore multiple treatment approaches, including CS5001 monotherapy and combination therapies for both lymphomas and solid tumors.
- The European Society for Medical Oncology has incorporated CStone's Cejemly® (sugemalimab) into its NSCLC treatment guidelines, recommending it as a first-line combination therapy for both squamous and non-squamous lung cancer. - Phase III GEMSTONE-302 trial demonstrated significant improvements in progression-free survival and overall survival when sugemalimab was combined with platinum-based chemotherapy across various PD-L1 expression levels. - The therapy received an ESMO-MCBS score of 4, indicating substantial clinical benefit, and has already gained regulatory approval in China, the EU, and the UK.
- Zilovertamab vedotin combined with R-CHP achieved a 100% complete response rate in untreated diffuse large B-cell lymphoma patients in a Phase 2 trial. - CS5001 demonstrated an overall objective response rate of 48.4% across all dose levels in patients with advanced lymphomas, showing activity in both solid tumors and lymphomas. - ROR1 is a promising target due to its overexpression in various cancers and its role in tumor growth and metastasis, making it a focus for novel therapies. - Clinical trials are underway for multiple ROR1-targeting therapies, including ADCs, bispecific antibodies, and CAR-T cell therapy, offering new options for cancer patients.
- CStone Pharmaceuticals will present clinical data on CS5001, an anti-ROR1 ADC, at the American Society of Hematology Annual Meeting. - CS5001 exhibited substantial anti-tumor activity, achieving a 43.5% objective response rate in advanced B-cell lymphoma cases. - The ongoing global Phase I trial of CS5001 suggests a potential breakthrough in the treatment of advanced B-cell lymphomas. - Investors and stakeholders are closely monitoring CS5001's development as CStone expands its clinical program.
